ImmuPharma (LON:IMM) Stock Price Crosses Below Two Hundred Day Moving Average – Here’s Why

ImmuPharma plc (LON:IMM)’s stock price passed below its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of GBX 5.84 and traded as low as GBX 4.34. ImmuPharma shares last traded at GBX 4.44, with a volume of 1,370,758 shares trading hands.

ImmuPharma Stock Up 5.4%

The firm has a 50 day moving average of GBX 4.48 and a two-hundred day moving average of GBX 5.84. The firm has a market capitalization of £30.01 million, a price-to-earnings ratio of -13.00 and a beta of 2.98.

ImmuPharma (LON:IMM) last released its quarterly earnings data on Wednesday, May 27th. The company reported GBX (0.37) earnings per share for the quarter. ImmuPharma had a net margin of 3,519.56% and a negative return on equity of 1,397.44%. Sell-side analysts forecast that ImmuPharma plc will post -339.0000022 EPS for the current fiscal year.

About ImmuPharma

ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.